&bull Trendlines holds approximately 38% in Limaca. This commercial agreement underscores Trendlines&rsquo portfolio strength and innovation in breakthrough medical companies.

&bull Founded and incubated by Trendlines, Limaca has developed an automated endoscopic biopsy solution Precision-GI&trade for gastrointestinal cancer diagnosis

&bull This strategic distribution partnership enables nationwide access to Precision-GI&trade motorized EUS biopsy and supports broader adoption in GI cancer diagnostics

 

The Trendlines Group Ltd. (SGX: 42T OTCQX: TRNLY), an investment group focused on agrifood and medtech innovation, today announced that its portfolio company Limaca Medical Ltd. (&ldquo Limaca&rdquo ), a commercial-stage medical device company advancing automated endoscopic biopsy solutions for gastrointestinal cancer diagnosis, has entered into an exclusive U.S. distribution agreement with a global leader in endoscopy equipment. Under the agreement, the global medical company will serve as Limaca' s exclusive U.S. distribution partner for its Precision-GI&trade automated biopsy system.

 

The exclusive U.S. distribution agreement with a leading medical equipment company marks an important commercial step for Limaca, enabling the wider clinical rollout of Precision-GI&trade through an

established partner in the endoscopy market.

 

This agreement enhances Limaca&rsquo s commercial footprint and market visibility in the United States and is expected to facilitate broader clinical adoption of automated EUS-guided biopsy, supported by the availability of TPT reimbursement.

 

&ldquo This agreement endorses the validation of the quality and commercial potential within the Trendlines portfolio,&rdquo added Haim Brosh, CEO of Trendlines. &ldquo We are proud to support companies that not only deliver innovation but also create meaningful impact in healthcare.&rdquo